H.C. Wainwright initiated coverage of Solid Biosciences with a Buy rating and $9 price target. Solid is a soon-to-be clinical-stage biopharmaceutical company focused on developing novel adeno-associated virus-based gene transfer therapies for rare neuromuscular and cardiac genetic diseases, the analyst tells investors in a research note. The firm says the company has built a deep and diversified pipeline across various indications.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SLDB:
- Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference
- FDA clears Solid Biosciences’ IND for Duchenne gene therapy candidate SGT-003
- Solid Biosciences reports Q3 net loss $21M vs $20.4M last year
- Solid Biosciences Provides Third Quarter Business Update and Financial Results
- Solid Biosciences participates in a conference call with JPMorgan
